- estradiol hemihydrate
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.
The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: PL46302/0036, PL46302/0035.
Femoston 1/10mg and 2/10mg
PACKAGE LEAFLET: INFORMATION FOR THE USER
femoston® 1/10 mg
femoston® 2/10 mg
Active substances: oestradiol hemihydrate and Dydrogesterone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Femoston is and what it is used for
2. What you need to know before you take Femoston
3. How to take Femoston
4. Possible side effects
5. How to store Femoston
6. Contents of the pack and other information
1. WHAT FEMOSTON IS AND WHAT IT IS USED FOR
Femoston is a Hormone Replacement Therapy (HRT). It contains two types of female hormones, an oestrogen and a progestogen. HRT is used in woman who require oestrogen replacement and who have not had their womb removed (hysterectomy). Femoston is used in postmenopausal women at least 6 months since last menses.
Femoston is used for:
Relief of symptoms occurring after menopause
During the menopause, the amount of oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest (“hot flushes”). Femoston alleviates these symptoms after menopause. You will only be prescribed Femoston if your symptoms seriously hinder your daily life.
Prevention of osteoporosis
After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor. If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Femoston to prevent osteoporosis after menopause.
2. BEFORE YOU TAKE FEMOSTON
Medical history and regular check-ups
The use of HRT carries risks which need to be considered when deciding whether to start taking it, or whether to carry on taking it. The experience in treating women with a premature menopause (due to ovarian failure or surgery) is limited. If you have a premature menopause the risks of using HRT may be different. Please talk to your doctor. Before you start (or restart) HRT, your doctor will ask about your own and your family’s medical history. Your doctor may decide to perform a physical examination. This may include an examination of your breasts and/or an internal examination, if necessary. Once you have started on Femoston you should see your doctor for regular check-ups (at least once a year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Femoston. Go for regular breast screening, as recommended by your doctor.
Do not take Femoston
If any of the following applies to you. If you are not sure about any of the points below, talk to your doctor before taking Femoston,
Do not take Femoston
If any of the above conditions appear for the first time while taking Femoston, stop taking it at once and consult your doctor immediately.
When to take special care with Femoston
Tell your doctor if you have ever had any of the following problems, before you start the treatment, as these may return or become worse during treatment with Femoston. If so, you should see your doctor more often for check-ups:
Stop taking Femoston and see a doctor immediately
If you notice any of the following when taking HRT:
For more information, see ‘Blood clots in a vein (thrombosis)’
Note: Femoston is not a contraceptive. If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to your doctor for advice.
HRT and cancer
Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer)
Taking oestrogen-only HRT will increase the risk of excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the womb lining (endometrial cancer).
The progestogen in Femoston protects you from this extra risk.
You may have irregular bleeding or drops of blood (spotting) during the first 3-6 months of taking Femoston. However, if the irregular bleeding:
see your doctor as soon as possible.
You will have a bleed once a month (so-called withdrawal bleed) while taking Femoston. But, if you have unexpected bleeding or drops of blood (spotting) besides your monthly bleeding, which:
see your doctor as soon as possible
Evidence suggests that taking combined oestrogenprogestogen and possibly also oestrogen-only HRT increases the risk of breast cancer. The extra risk depends on how long you take HRT. The additional risk becomes clear within a few years. However, it returns to normal within a few years (at most 5) after stopping treatment.
Women aged 50 to 79 who are not taking HRT, on average, 9 to 14 in 1000 will be diagnosed with breast cancer over a 5-year period. For women aged 50 to 79 who are taking oestrogen-progestogen HRT over 5 years, there will be 13 to 20 cases in 1000 users (i.e. an extra 4 to 6 cases).
Ovarian cancer is much rarer than breast cancer. The use of oestrogen-only or combined oestrogen-progestogen HRT has been associated with a slightly increased risk of ovarian cancer. The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years, there will be about 3 cases per 2000 users (i.e. about 1 extra case).
Effect of HRT on heart and circulation Blood clots in a vein (thrombosis)
The risk of blood clots in the veins is about 1.3 to 3- times higher in HRT users than in non-users, especially during the first year of taking it. Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death.
You are more likely to get a blood clot in your veins as you get older and if any of the following applies to you. Inform your doctor if any of these situations applies to you:
For signs of a blood clot, see “Stop taking Femoston and see a doctor immediately”.
Looking at women in their 50s who are not taking HRT, on average, over a 5-year period, 4 to 7 in 1000 would be expected to get a blood clot in a vein. For women in their 50s who have been taking oestrogen-progestogen HRT for over 5 years, there will be 9 to 12 cases in 1000 users (i.e. an extra 5 cases).
Heart disease (heart attack)
There is no evidence that HRT will prevent a heart attack. Women over the age of 60 years who use oestrogen-progestogen HRT are slightly more likely to develop heart disease than those not taking any HRT.
The risk of having a stroke is about 1.5 times higher in HRT users than in non-users. The number of extra cases of stroke due to use of HRT will increase with age.
Looking at women in their 50s who are not taking HRT, on average, 8 in 1000 would be expected to have a stroke over a 5-year period. For women in their 50s who are taking HRT, there will be 11 cases in 1000 users, over 5 years (i.e. an extra 3 cases).
Using other medicines
Some medicines may interfere with the effect of Femoston. This might lead to irregular bleeding. This applies to the following medicines:
Problems due to high levels of the following medicines may occur when you take Femoston so careful drug monitoring and dose decrease may become necessary:
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines including medicines obtained without a prescription, herbal medicines or other natural products.
If you need a blood test, tell your doctor or the laboratory staff that you are taking Femoston, because this medicine can affect the results of some tests.
Pregnancy and breast-feeding
Femoston is for use in postmenopausal women only.
If you become pregnant, stop taking Femoston and contact your doctor.
3. HOW TO TAKE FEMOSTON
Always take Femoston exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
How to take Femoston
Take one tablet every day, without a break between packs. Swallow the tablet with water, with or without food. Your doctor will aim to give you the lowest dose for the shortest time to treat your symptoms.
Speak to your doctor if you think this dose is too strong or not strong enough. The usual starting dose is:
During day 1 to 14 of the cycle, 1 tablet daily containing 1 or 2 mg oestradiol.
During day 15 to 28 of the cycle, 1 tablet daily containing 1 or 2 mg oestradiol and 10 mg dydrogesterone.
Immediately after the 28-day cycle you should begin the next treatment.
The days of the week are printed on the back of the blister strips. The tablets from the part marked with arrow 1 should be taken first, then the tablets from the part marked with arrow 2 should be taken. If you are not having periods and are not taking any other Hormone Replacement Therapy (HRT) preparations, or you are switching from a combined continuous HRT product, you can start taking Femoston on any convenient day.
If you are currently using a ‘cyclic’ or ‘sequential’ HRT preparation (which involves taking an oestrogen tablet or patch for part of the month, followed by both oestrogen and progestagen tablet or patch for up to 14 days) start taking Femoston the day after you finish the pack i.e. at the end of the progestagen phase. The doctor may increase the dose later, if necessary. The different tablet strengths are colour-coded for your convenience. If you are taking Femoston to treat symptoms of the menopause (change of life), your treatment should begin with the dosage Femoston 1/10. Your doctor will then increase this dose according to your symptoms. If you are taking Femoston to prevent osteoporosis, your doctor will adjust the dose individually according to your bone mass.
If you take more Femoston than you should
If you or somebody else takes too many Femoston tablets, they are unlikely to come to any harm. Nausea (feeling sick), vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue, and withdrawal bleeding may occur. No treatment is necessary, but if you are worried contact your doctor for advice.
If you forget to take Femoston
Take the missed tablet as soon as you remember. If it is more than 12 hours since you took the last one, take the next dose without taking the forgotten tablet. Do not take a double dose. Bleeding or spotting may occur if you miss a dose.
If you stop taking Femoston
Do not stop taking Femoston without first talking to your doctor. If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you need to have surgery
If you are going to have surgery, tell the surgeon that you are taking Femoston. You may need to stop taking Femoston about 4 to 6 weeks before the operation to reduce the risk of a blood clot (see section 2, Blood clots in a vein). Ask your doctor when you can start taking Femoston again.
4. POSSIBLE SIDE EFFECTS
Like all medicines, Femoston can cause side effects, although not everybody gets them.
The following diseases are reported more often in women using HRT compared to women not using HRT:
For more information about these side effects, see Section 2.
The following serious side effects may occur during treatment with Femoston:
If any of these side effects occur you should stop treatment immediately and contact your doctor. The following side effects may occur during treatment:
Very common (in more than 1 in 10 patients treated):
Common (in less than 1 in 10, but more than 1 in 100 patients treated):
Uncommon (in less than 1 in 100, but more than 1 in 1,000 patients treated):
Rare (in less than 1 in 1,000, but more than 1 in 10,000 patients treated):
If unscheduled bleeding occurs after some time on HRT, you should contact your doctor. If unscheduled bleeding continues after stopping HRT, it may be necessary to perform tests to exclude disease of the endometrium (the lining of the uterus). Changes can occur in the levels of certain proteins and hormones in the blood. The action of the hormones in the body is not affected. You should tell your doctor that you are taking HRT if you are to have a blood test.
The following side effects have been reported with HRTs (including Femoston):
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting systems listed below.
In the UK:
The Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
5. HOW TO STORE FEMOSTON
Keep out of the reach and sight of children. This medicinal product does not require any special storage conditions.
Do not take Femoston after the “use before” date, which is stated on the pack. The “use before” date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
6. FURTHER INFORMATION
What Femoston contains
Contains 14 white tablets with 1 mg oestradiol per tablet for the first 14 days of the cycle and 14 grey tablets with 1 mg oestradiol and 10 mg dydrogesterone for the second 14 days of the cycle.
Contains 14 brick red tablets with 2 mg oestradiol per tablet for the first 14 days of the cycle and 14 yellow tablets with 2 mg oestradiol and 10 mg dydrogesterone for the second 14 days of the cycle.
What Femoston looks like and contents of the pack
Femoston 1/10 Round white film-coated tablets and round grey film-coated tablets. The inscription on the tablets is ‘379’ on one side. The tablets are packed in a PVC film with a covering aluminium foil. The blister packs contain 84 film-coated tablets.
Femoston 2/10 Round brick red film-coated tablets and round yellow film-coated tablets. The inscription on the tablets is ‘379’ on one side. The tablets are packed in a PVC/PVdC or PVC film with a covering aluminium foil.
The blister packs contain 28 or 84 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
This leaflet was last revised in September 2016.
Building 4, Trident Place, Mosquito Way, Hatfield, Herts, AL10 9UL, UK
+44 (0) 800 1218 267
+44 (0)1707 853 000